Trials / Unknown
UnknownNCT06243432
Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer
Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CYCLHER is a retrospective observational multicentric italian study aimed to evaluate the correlation between hormone receptors (HR) and HER2 immunohistochemistry (IHC) levels and treatment'response in patients affected by advanced breast cancer treated with first line CDK4/6 inhibitor plus endocrine therapy.
Conditions
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2024-12-31
- Completion
- 2025-03-01
- First posted
- 2024-02-06
- Last updated
- 2024-04-24
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06243432. Inclusion in this directory is not an endorsement.